Lonza expands capsule manufacturing capacity in India and China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
This facility marks a significant milestone in transforming the global food industr
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Subscribe To Our Newsletter & Stay Updated